CompletedPhase 3NCT01404234
Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Mark Bresnik, M.D.Gilead Sciences
- Intervention
- AZLI(drug)
- Enrollment
- 61 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2011 – 2013
Study locations (29)
- The Children's Hospital - Denver, Aurora, Colorado, United States
- Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States
- Children's Memorial Hospital, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States
- SUNY Upstate Medical University, Syracuse, New York, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Baylor College of Medicine, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- C.H.U de Bordeaux, Bordeaux, France
- Centre Hospitalier Robert Bissons, Lisieux, France
- Hopital Necker Enfants Malades, Paris, France
- Charite Campus Virchow Klinikum, Berlin, Germany
- Universitatsklinik St. Josef-Hospital, Bochum, Germany
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01404234 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.